July 2009
Volume 4, Issue 8
Click Here

Drug Discovery Today    Latest issue    DDT home    

The View
from Here

Paul Workman

In this issue we will be dealing with the subject of Systems Biology and its impact on Drug Discovery. The term ?Systems Biology? has been used since around about 1966 but it was at the turn of the new millennium that the movement really began to develop some momentum...


Upcoming Issues

Nanotechnology in drug delivery

Stem Cells

Editor's Choice

Sign Up for email

Update your details


Contact Us

  Top Reviews
a The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
Juillerat-Jeanneret L
Drug Discovery Today

One of the most challenging problems, if not the most challenging, in drug development is not to develop drugs to treat diseases of the central nervous system (CNS), but to manage to distribute them to the CNS across the blood–brain barrier (BBB) using transvascular routes following intravenous administration...
a Development trends for new cancer therapeutics and vaccines
Reichert JM, Wenger JB
Drug Discovery Today

Global commercial development of cancer treatments has dramatically increased over the past 15 years. To assess trends in the process, we analyzed data for 1111 candidates that entered clinical study during 1990–2006...
a The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Cvek B, Dvorak Z
Drug Discovery Today

The major approach to the development of anticancer drugs involves searching for new compounds, efficient against malignancies, which are not, as yet, used clinically. This strategy is time-consuming and expensive...

  Abstracts of Key Research Articles

Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009 Jul;9(7):489-99.

Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008 Apr 3;452(7187):580-9.

Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven Brandon A, Di Stefano F, Hayes A, Henley AT, Lensun L, Pergl-Wilson G, Robson A, Saghir N, Zhyvoloup A, McDonald E, Sheldrake P, Shuttleworth S, Valenti M, Wan NC, Clarke PA, Workman P. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009 Jul;8(7):1725-38

Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol. 2009 May;6(5):259-65.

Menard D, Niculescu-Duvaz I, Dijkstra HP, Niculescu-Duvaz D, Suijkerbuijk BM, Zambon A, Nourry A, Roman E, Davies L, Manne HA, Friedlos F, Kirk R, Whittaker S, Gill A, Taylor RD, Marais R, Springer CJ. Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl Ring. J Med Chem. 2009 May 27. [Epub ahead of print]

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 Jul 9;361(2):123-34.

Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009 Apr 9;458(7239):719-24.

Attard G, Reid AH, A'hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS. Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer. J Clin Oncol. 2009 May 26. [Epub ahead of print]

Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell. 2008 Sep 9;14(3):250-62.

Cho CR, Labow M, Reinhardt M, van Oostrum J, Peitsch MC. The application of systems biology to drug discovery. Curr Opin Chem Biol. 2006;10(4):294-302.

Data Protection Notice:

This email has been sent to email-address from Elsevier Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, registered in England with registered number 1982084, using Email Reaction’s Technology and Platform.

You are receiving this email because you were a registered user of BioMedNet and requested to receive Gateway Alerts or are a subscriber to Drug Discovery Today. To unsubscribe from this email alert service or sign up for others, click here.

For all inquiries, problems or suggestions regarding this service, please contact DDT@drugdiscoverytoday.com

Copyright © 2007 Elsevier Ltd. All rights reserved. Please read the Elsevier Alerts Privacy Policy and the E-Mail Reaction Privacy Policy.